Impact of chemotherapy on the mother-placenta-fetus system: the current status of the problem


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The paper comparatively analyzes the results of investigations published in the scientific literature and devoted to the impact of chemotherapy on maternal and fetal health. It considers recommendations to change the existing pregnancy management algorithms in patients with cancers. Further investigations will be able to find a reasonable approach to solving the problem associated with the effective treatment of cancer in a pregnant patient provided that her child’s health is preserved.

Full Text

Restricted Access

About the authors

Aminat I. Akhmedova

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after Academician V.I. Kulakov, Ministry of Health of Russia

Email: a_ahmedova@oparina4.ru
postgraduate student

Lyudmila A. Lyubasovskaya

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after Academician V.I. Kulakov, Ministry of Health of Russia

Email: l_lyubasovskaya@oparina4.ru
PhD, head of the department clinical pharmacology

Igor I. Miroshnichenko

Mental Health Research Center, Russian Academy of Sciences

Email: igormir@psychiatry.ru
MD, PhD, Head of Pharmacokinetics Laboratory

Natalia V. Baimeeva

Mental Health Research Center, Russian Academy of Sciences

Email: baymeeva_n@mail.ru
Junior Researcher, Pharmacokinetics Laboratory

Roman G. Shmakov

National Medical Research Center of Obstetrics, Gynecology, and Perinatology named after Academician V.I. Kulakov, Ministry of Health of Russia

Email: r_shmakov@oparina4.ru
MD, PhD, Chief medical officer

References

  1. Miyamoto S., Yamada M., Kasai Y., Miyauchi A., Andoh K. Anticancer drugs during pregnancy. Jpn. J. Clin. Oncol. 2016; 46(9): 795-804.
  2. Mitrou S., Zarkavelis G., Fotopoulos G., Petrakis D., Pavlidis N. A mini review on pregnant mothers with cancer: A paradoxical coexistence. J. Adv. Res. 2016; 7(4): 559-63.
  3. Dekrem J., Van Calsteren K., Amant F. Effects of fetal exposure to maternal chemotherapy. Paediatr. Drugs. 2013; 15(5): 329-34.
  4. Voulgaris E., Pentheroudakis G., Pavlidis N. Cancer and pregnancy: a comprehensive review. Surg. Oncol. 2011; 20(4): e175-85.
  5. Пароконная А.А., Шмаков Р.Г., Нечушкин М.И., Тюляндин С.А., Волочаева М.В. Современные методы лечения беременных больных раком молочной железы. Исследования и практика в медицине. 2015; 2(Приложение 1): 67.
  6. Сухих Г.Т., Давыдов М.И., Савченко В.Г., ред. Репродуктивное здоровье женщин с онкогематологическими заболеваниями. М.: Боргес; 2012: 22-5, 31-2, 44-9.
  7. Bell D.J., Kerr D.J. Pharmacokinetic considerations in the use of anticancer drugs during pregnancy: challenges and new developments. Expert Opin. Drug Metab. Toxicol. 2015; 11(9): 1341-4.
  8. Tasnif Y., Morado J., Hebert M.F. Pregnancy-related pharmacokinetic changes. Clin. Pharmacol. Ther. 2016; 100(1): 53-62.
  9. Costantine M.M. Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol. 2014; 5: 65.
  10. Isoherranen N., Thummel K.E. Drug metabolism and transport during pregnancy: how does drug disposition change during pregnancy and what are the mechanisms that cause such changes? Drug Metab. Dispos. 2013; 41(2): 256-62.
  11. Bardin C., Veal G., Paci A., Chatelut E., Astier A., Levêque D. et al. Therapeutic drug monitoring in cancer - Are we missing a trick? Eur. J. Cancer. 2014; 50(12): 2005-9.
  12. Kang J., Park Y.S., Kim S.H., Kim S.H., Jun M.Y. Modern methods for analysis of antiepileptic drugs in the biological fluids for pharmacokinetics, bioequivalence and therapeutic drug monitoring. Korean J. Physiol. Pharmacol. 2011; 15(2): 67-81.
  13. van Hasselt J.G., van Calsteren K., Heyns L., Han S., Mhallem Gziri M., Schellens J.H. et al. Optimizing anticancer drug treatment in pregnant cancer patients: pharmacokinetic analysis of gestation-induced changes for doxorubicin, epirubicin, docetaxel and paclitaxel. Ann. Oncol. 2014; 25(10): 2059-65.
  14. Lee N.Y., Lee H.E., Kang Y.S. Identification of P-glycoprotein and transport mechanism of paclitaxel in syncytiotrophoblast cells. Biomol. Ther. (Seoul). 2014; 22(1): 68-72.
  15. Staud F., Cerveny L., Ceckova M. Pharmacotherapy in pregnancy; effect of ABC and SLC transporters on drug transport across the placenta and fetal. J. Drug Target. 2012; 20(9): 736-63.
  16. Amant F., Han S.N., Gziri M.M., Dekrem J., Van Calsteren K. Chemotherapy during pregnancy. Curr. Opin. Oncol. 2012; 24(5): 580-6.
  17. Calsteren K.V., Verbesselt R., Beijnen J., Devlieger R., De Catte L., Chai D.C. et al. Transplacental transfer of anthracyclines, vinblastine, and 4-hydroxy-cyclophos-phamide in a baboon model. Gynecol. Oncol. 2010; 119(3): 594-600.
  18. Calsteren K.V., Verbesselt R., Devlieger R., De Catte L., Chai D.C., Van Bree R. et al. Transplacental transfer of paclitaxel, docetaxel, carboplatin, and trastu-zumab in a baboon model. Int. J. Gynecol. Cancer. 2010; 20(9): 1456-64.
  19. Berveiller P., Mir O. Taxanes during pregnancy: probably safe, but still to be optimized. Oncology. 2012; 83(4): 239-40.
  20. Berveiller P., Selleret L., Mir O. Drug selection and dosing in pregnant cancer patients: insights from clinical pharmacokinetics. Ann. Oncol. 2014; 25(10): 1869-70.
  21. Amant F., Van Calsteren K., Halaska M.J., Gziri M.M., Hui W., Lagae L. et al. Long-term cognitive and cardiac outcomes after prenatal exposure to chemotherapy in children aged 18 months or older: an observational study. Lancet Oncol. 2012; 13(3): 256-64.
  22. Avilès A., Nambo M.J., Huerta-Guzmàn J., Neri N., Cleto S. Speckle-tracking echocardiography to detect cardiac toxicity in children who received anthracyclines during pregnancy. Clin. Lymphoma Myeloma Leuk. 2016; 16(1): 1-4.
  23. Волочаева М.В., Шмаков Р.Г., Зубков В.В. Здоровье детей, рожденных женщинами с раком молочной железы, связанным с беременностью. Акушерство и гинекология. 2014; 7: 33-7. [Volochaeva M.V., Shmakov R.G., Zubkov V.V. The health of babies born to women with pregnancy-associated breast cancer. Akusherstvo i Ginekologiya/Obstetrics and Gynecology. 2014; (7): 33-7. (in Russian)]
  24. Amant F., Vandenbroucke T., Verheecke M., Fumagalli M., Halaska M.J., Boere I. et al.; International Network on Cancer, Infertility, and Pregnancy (INCIP). Pediatric outcome after maternal cancer diagnosed during pregnancy. N. Engl. J. Med. 2015; 373(19): 1824-34.
  25. Peccatori FA., Azim H.A. Jr., Orecchia R., Hoekstra H.J., Pavlidis N., Kesic V., Pentheroudakis G.; ESMO Guidelines Working Group. Cancer, pregnancy and fertility: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2013; 24(Suppl. 6): vi160-70.
  26. Odelia A., Erel J., Chava P., Yair H., Nadav S., Michael L., Irit A. Continuing dilemmas in the management of lymphoma during pregnancy: review of a 10-point case-based questionnaire. Int. J. Clin. Oncol. 2017; 22(1): 190-9.
  27. Van Calsteren K., Heyns L., De Smet F., Van Eycken L., Gziri M.M., Van Gemert W. et al. Cancer during pregnancy: an analysis of 215 patients emphasizing the obstetrical and the neonatal outcomes. J. Clin. Oncol. 2010; 28(4): 683-9.
  28. Volochaeva M.V., Polushkina E.S., Makieva M.I., Shmakov R.G., Zubkov V.V., Akhmedova A.I., Kozirko E.V. Health of children born by mothers with cancer. In: 6th International conference on clinical neonatology. Turin 22-24 September 2016. Abstract ID: 106.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies